StreetInsider.com News Articles

Form 8-K Barinthus Biotherapeutic For: May 20

Thu, 21 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260521/26530906.html

Form 8-K Barinthus Biotherapeutic For: May 20

Thu, 21 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260521/26530906.html

Form 3 Barinthus Biotherapeutic For: May 01 Filed by: Swirsky Douglas J

Fri, 01 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260501/26417868.html

Form 3 Barinthus Biotherapeutic For: May 01 Filed by: Swirsky Douglas J

Fri, 01 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260501/26417868.html

Barinthus Biotherapeutics plc (BRNS) Tops Q1 EPS by 18c

Fri, 01 May 2026 09:05:34 -0400

Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported Q1 EPS of ($0.14), $0.18 better than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Barinthus Biotherapeutics plc (BRNS) click here.

Form 10-Q Barinthus Biotherapeutic For: Mar 31

Thu, 30 Apr 2026 07:43:00 -0400

si-local-file:///var/storage/secattach/20260430/26400768.html

Form 10-Q Barinthus Biotherapeutic For: Mar 31

Thu, 30 Apr 2026 07:43:00 -0400

si-local-file:///var/storage/secattach/20260430/26400768.html

Form 8-K Barinthus Biotherapeutic For: Apr 30

Thu, 30 Apr 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260430/26400694.html

Form 8-K Barinthus Biotherapeutic For: Apr 30

Thu, 30 Apr 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260430/26400694.html

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Thu, 30 Apr 2026 07:30:00 -0400

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing
Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026

GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Thu, 30 Apr 2026 07:30:00 -0400

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing
Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Thu, 30 Apr 2026 07:30:00 -0400

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing
Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Thu, 30 Apr 2026 07:30:00 -0400

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing
Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026

Form DEFM14A Barinthus Biotherapeutic

Thu, 30 Apr 2026 06:16:00 -0400

http://archive.fast-edgar.com/20260430/A2B2EQ2C8Z22CZZ222JV2ZZZS2T4R2W2D282

Filed on: April 30, 2026

Form DEFM14A Barinthus Biotherapeutic

Thu, 30 Apr 2026 06:16:00 -0400

http://archive.fast-edgar.com/20260430/A2B2EQ2C8Z22CZZ222JV2ZZZS2T4R2W2D282

Filed on: April 30, 2026

Form 8-K Barinthus Biotherapeutic For: Apr 22

Wed, 22 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260422/26351975.html

Form 8-K Barinthus Biotherapeutic For: Apr 22

Wed, 22 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260422/26351975.html

Form SCHEDULE 13D Barinthus Biotherapeutic Filed by: International Generosity Foundation Trust

Mon, 13 Apr 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260413/26305458.html

Form SCHEDULE 13D Barinthus Biotherapeutic Filed by: International Generosity Foundation Trust

Mon, 13 Apr 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260413/26305458.html

Form 8-K Barinthus Biotherapeutic For: Mar 27

Tue, 31 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260331/26250718.html

Form 8-K Barinthus Biotherapeutic For: Mar 27

Tue, 31 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260331/26250718.html

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

Mon, 16 Mar 2026 15:20:00 -0400

NEW YORK, March 16, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

Barinthus Biotherapeutics plc (NASDAQ: BRNS) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

Mon, 16 Mar 2026 15:20:00 -0400

Barinthus Biotherapeutics plc (NASDAQ: BRNS) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

Mon, 16 Mar 2026 15:20:00 -0400

Barinthus Biotherapeutics plc (NASDAQ: BRNS) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

Mon, 16 Mar 2026 15:20:00 -0400

Barinthus Biotherapeutics plc (NASDAQ: BRNS) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus